Lymphocyte function-associated antigen 1 dominates very late antigen 4 in binding of activated T cells to endothelium by unknown
Brief Det;nltive  Report 
Lymphocyte  Function-associated Antigen  1 Dominates 
Very Late Antigen 4  in Binding of Activated T  Cells 
to Endothelium 
By Yvette van Kooyk, EUy van de Wiel-van Kemenade, 
Pauline Weder, Richard  J. F. Huijbens, and Carl G. Figdor 
From the Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, 
The Netherlands 
Sunll~al-y 
Lymphocyte function-associated antigen 1/intercellular adhesion moleculer 1 (LFA-1/ICAM-1)- 
and very late antigen 4/vascular cell adhesion molecule 1 (VLA-4/VCAM-1)-mediated adhesion 
of T lymphocytes to endothelial cells (EC) can be regulated by increased expression of ICAM-1 
and VCAM-1 upon cytokine treatment of EC, or by activation of the integrin molecules LFA-1 
and VLA-4 on T cells. Here, we provide evidence that preferential usage of LFA-1 over VLA-4 
is yet another mechanism to control T  cell adhesion. We observed that binding of activated 
T lymphocytes, as opposed to resting T cells, to EC is essentially mediated through LFA-1 and 
not through VLA-4. VLA-4-mediated adhesion of T  cells to EC is only found when LFA-1 is 
not expressed or not functional, as observed for several T cell leukemia cell lines.  These results 
suggest that LFA-l-mediated adhesion dominates and may downregulate VLA-4-mediated adhesion 
through an unidentified mechanism. 
dhesion of T  lymphocytes to endothelium, lining the 
blood vessels, is a crucial step in immune surveillance. 
It allows T lymphocytes to recirculate and migrate into sites 
of inflammation (1). Different adhesion receptors have been 
described to be involved in this process (2, 3). The integrins 
LFA-1 and very late antigen 4 (VLA-4), which are both ex- 
pressed on T  cells,  have been reported to mediate binding 
to endothelial cells (EC) (4-7). One mechanism to regulate 
adhesion of T lymphocytes to endothelial cells involves acti- 
vation of EC by inflammatory cytokines such as TNF-a, 
which results in a rapid increase in the expression of intercd- 
lular adhesion molecule 1 (ICAM-1) and vascular cell adhe- 
sion molecule 1 (VCAM-1), ligands of LFA-1 and VLA-4, 
respectively (3,  8).  Kecently, the activation state of these 
integrin molecules expressed by T cells also has been described 
to play an important role in the regulation of the adhesion 
function of these cells (9-13). Here we demonstrate that yet 
another mechanism can regulate cell adhesion. By using an 
antibody (NKI-L16)  that recognizes an activation epitope 
(termed L16) on LFA-1 (9, 14), we observed that the func- 
tional state of the LFA-1 molecule, as reported by this anti- 
body, determines if LFA-1 or VLA-4 is exploited by T cells 
to bind EC. The results suggest that, only when LFA-1 is 
not capable to mediate adhesion, VLA-4 is used by T lym- 
phocytes to bind EC, pointing to a selective use of these adhe- 
sion receptors by T  cells. 
Materials and Methods 
Reagents and Antibodies.  The mAbs used in this study were SPV- 
L7 directed against the c~ chain of LFA-1 (CD11a; 15), NKI-L16 
directed against a Ca2+-dependent epitope on LFA-lcx (CD11a*; 
16), CLB LFA-1/1 reactive with the/32 chain (CD18; 16); F10.2 
(anti-ICAM-1, CD54); HP2/1 (anti-VLA-4, CD49d; 17); TS2/16 
directed against/31 (CD29; 18); 4B9 (anti-VCAM-1); and ENA-1 
(anti-endothelial leukocyte adhesion molecule 1 [ELAM-1]). Re- 
agents used were human ffNF-tx (100 U/m1; supernatant of cDNA- 
transfected  COS cells), phorbol ester PMA (50 ng/ml; Sigma Chem- 
ical Co., St. Louis, MO), and fibronectin (FN) (20 #g/ml; Sigma 
Chemical Co.). 
Cells.  The T cell clone JS136 used in this study was cultured 
as described previously (9). The LFA-l-deficient  T cell clone (LAD 
6.6) was raised from PBL of a patient suffering from the leukocyte 
adhesion deficiency  (LAD) syndrome (19) and was cultured under 
same conditions as T ceil clone JS136. The human leukemic T cell 
lines Jurkat and CEM were cultured in Iscove's medium containing 
5% FCS. A homogenous population of highly purified T lympho- 
cytes was isolated by centrifugal dutriation (9), and cultured in 
Iscove's medium containing 5% FCS and IL-2 (100 U/ml; Cetus 
Corp., Emeryville, CA) for 24 h. L-ICAM-1 cells were obtained 
by transfection of ICAM-1 cDNA into mouse fibroblast L ceUs. 
ICAM-1  expression was high  (95%;  mean,  45)  and  remained 
throughout culture of the ceils in the presence of Hygromycin B 
(200 #g/ml; Schering Research, Bloomfield, NJ), Human EC were 
isolated from umbilical vein by coUagenase  digestion, and cultured 
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used for adhesion experiments. 
Clustering Assay.  Binding of T cells to DICAM-1 cells was de- 
termined  by means of double fluorescence. Cells (106/ml) were 
stained with the green dye sulfofluorescein diacetate (SFDA; Mo- 
lecular Probes, Junction City, OK) at a concentration of 5/zg/ml 
or with the red dye Hydroethidine  (HE; Polyscience Inc., War- 
rington, PA) at a concentration of 3 ng/ml, as described previously 
(9). 10  s red-labeled cells and 10  s green-labeled cells were incubated 
at 37~  for different periods of time in Iscove's  medium containing 
0.5% BSA, and stimulated with PMA (50 ng/ml). Subsequently, 
cells were fixed with 0.5% (wt/vol) paraformaldehyde, and heter- 
otypic conjugates were measured by FACScan  |  analysis (Becton 
Dickinson & Co., Mountain View, CA). Data are representative 
of four experiments. 
Adhesion Assay.  Human EC were seeded at 2  x  10  s cells/ml 
in FN-coated (2/xg/ml) 96-well  plates and were stimulated for 24 h 
with human ffNF-o~ (100 U/ml). Adhesion experiments were per- 
formed as described previously (20). Briefly, SlCr-labeled T cells 
were allowed to bind at 37~  for 30 min. The number of adherent 
T cells was quantified in a gamma counter. Results are expressed 
as the mean percentage of cells binding from triplicate wells. For 
inhibition studies, cells  were preincubated (30 min, 4~  with 1:100 
ascites dilution or 10 #g/ml purified mAb. Data are representative 
for four experiments.  For adhesion  experiments  to VCAM-1, purified 
soluble VCAM-1 (21) (0.8 #g/ml) was coated for 16 h at 4~  Sub- 
sequently, wells were coated by 1% (wt/vol) BSA for 1 h at 37~ 
T cell adhesion was performed under the same conditions as de- 
scribed for EC. 
Immunofluorescence.  Cells  were incubated for 30 rain at 4~  in 
PBS, 0.5% (wt/vol) BSA, 0.2% azide with appropriate dilutions 
of the  mAb,  followed by incubation  with  FITC-labeled  goat 
(Fab')2 anti-mouse IgG antibody (GAM-FITC; Nordic, Tilburg, 
the Netherlands) for 30 min at 4~  The relative fluorescence in- 
tensity was measured by FACscan  |  analysis (Becton Dickinson and 
Co.). 
Results and Discussion 
The  contribution  of the  LFA-1/ICAM-1  and  VLA-4/ 
VCAM-1 adhesion receptor pairs in T  cell-EC interactions 
was examined by binding of resting and activated T cells to 
24-h TNF-ot-cultured EC,  which expressed high levels of 
ICAM-1 and VCAM-1, and only low levels of ELAM-1 (Table 
1). LFA-1 + T  cells (JS136, PBL, CEM, and Jurkat) as well 
as  LFA-1-  T  cells  (LAD  6.6),  obtained  from  a  patient 
suffering the LAD syndrome (19), showed significant binding 
to TNF-c~-stimulated EC (Fig.  1 A). Interestingly, we ob- 
served that, although approximately equal numbers of the 
different cell types bound to EC (except resting PBL), dis- 
tinct receptor pairs were used to mediate adhesion. T  cell 
clone JS136  and IL-2-cultured lymphocytes showed LFA-1- 
restricted adhesion (blocked by anti-CD18 antibodies; Fig. 
1 B). In contrast, the LFA-1- T  cell clone (LAD 6.6) and 
two LFA-1 + T cell lines (CEM and Jurkat) bound to TNF- 
c~-EC exclusively through VLA-4 (Fig. 1 B). Compared with 
the cultured T cells, binding of freshly isolated lymphocytes 
to TNF-o~-stimulated EC was significantly lower (Fig. 1 A) 
and was mediated both by LFA-1 and VLA-4 (Fig. 1 B). An- 
tibodies directed against ICAM-1 and VCAM-1 blocked the 
adhesion of the cells to the same extent as anti-LFA-1 or anti- 
VLA-4 antibodies, respectively (not shown). Antibodies to 
ELAM-1 did not block the adhesion, indicating that ELAM-1 
is not involved in this process (not shown; 20). These results 
indicate that only resting PBL use both adhesion pathways 
(LFA-1/ICAM-1 and VLA-4/VCAM-i). Upon in vitro cul- 
ture of PBL there is a tendency towards LFA-l-dependent/ 
VLA-4-independent adhesion, whereas fully activated T cells, 
like a T  cell clone (several other T  cell clones were studied; 
not shown), exclusively use LFA-1 but not VLA-4. In con- 
Table  1.  Expression of Cell Adhesion  Molecules on Different  T  Cells and Endothelial Cells 
Relative fluorescence intensity 
T  cells  Cultured endothelial cells 
mAb  Antigen  JS136  Ly  Ly IL-2  Jurkat  CEM  LAD 6.6  Medium  24 h TNF-c~ 
GAM-FITC  Control  2  1  1  2  3  3  2  4 
SPV-L7  LFA-1  307  44  42  40  31  4  1  1 
NKI-L16  LFA-I*  304  19  31  3  5  3  2  3 
HP 2/1  VLA-4  74  41  30  23  46  130  1  1 
F10.2  ICAM-1  40  5  21  16  14  29  44  394 
4B9  VCAM-1  2  2  3  3  2  3  4  73 
ENA-1  ELAM-1  3  6  5  4  4  4  6  14 
Lymphocytes (Ly) were freshly isolated or cultured for 24 h with 100 U/ml IL-2 (Ly IL-2). The LFA-1  + and LFA-1- T cell clones JS136 and 
LAD6.6, respectively,  and the T ceU lines  Jurkat and CEM were cultured as described  in Materials and Methods. The EC were activated  by culturing 
for 24 h in the presence  of 100 U/ml TNF-ot. Antigen expression  was determined  by immunofluorescence.  One representative  experiment out of 
four is shown. 
" Ca2+-dependent epitope. 
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Figare 1.  Adhesion  of T cells to 24-h TNF-oe-stimulated  endothelial 
cells, LFA-1  + T cells: T cell clone JSD6, freshly isohted lymphocytes (Ly), 
lymphocytes cultured for 24 h with 100 U/ml IL-2 (Ly IL-2), and T ceU 
lines Jurkat and CEM. LFA-1- T cells: T cell done LAD 6.6. (,4) T cells 
were slCr hbded  and were allowed to adhere  for 30 rain at 37~  to 
24-h  TNF-a (100 U/ml)-stimulated endothdial cells. (B) Percentage of 
inhibition of T cells to TNF-o~-stimulated EC by anti-CD18 antibodies 
(I) or anti-VI.A-4 antibodies  (l~), showing the contribution of LFA-1, 
compared  with VLA-4, in binding to EC. (C) Inhibition of a combina- 
tion ofanti-CD18 and anti-VLA-4 antibodies. The SE bars represent three 
independent  tests within the experiment.  One representative experiment 
out of four is shown. 
trast to this shift from LFA-1/VLA-4-mediated  adhesion to 
only LFA-l-mediated adhesion, we observed that several  leu- 
kemic T cell lines that express significant levels of  LFA-1 (Table 
1) bind EC exclusively through VLA-4. In all cases adhesion 
of T  ceils to TNF-ot-stimulated  EC could not be blocked 
completely by anti-LFA-1 and anti-VLA-4 antibodies (up to 
60-80% of total adhesion; Fig. 1 C), indicating that other 
as yet undefined adhesion structures mediate the remaining 
20-40%  of adhesion. 
The selective use of LFA-1 or VLA-4 by T cells to mediate 
adhesion to EC prompted us to investigate the expression 
of these adhesion receptors in more detail (Table 1). All T 
cells expressed significant levels of VLA-4, indicating that 
in principle all cells are capable of using VLA-4 to mediate 
adhesion to TNF-c~-stimulated EC. As expected, LFA-1 ex- 
pression is totally absent on LAD T cells (LAD 6.6), thus 
explaining the VLA-4-mediated  binding to TNF-ot-stimulated 
EC.  However, all other T  calls expressed significant levels 
of LFA-1 (JS136, lymphocytes, CEM, and Jurkat). LFA-1 is 
expressed at much higher levels  on JSD6 compared with PBL, 
CEM, and Jurkat. Interestingly, we observed that expression 
of the L16 activation epitope, a Ca  z  +-dependent epitope on 
LFA-1, which recognizes a "potentially active" form of  LFA-1 
(9),  is  absent  on  the LFA-1  +  CEM  and Jurkat  T  cells, 
whereas expression is low on resting lymphocytes (9) and 
high on IL-2-cultured lymphocytes and on T cell doneJSD6. 
Earlier work indicated that expression of the L16 epitope is 
a prerequisite for LFA-1 to mediate cell adhesion (9, 14). This 
finding suggests that JS136 and IL-2-cultured PBL express 
a form of LFA-1 that can readily be activated to high-avidity 
ligand binding, whereas LFA-1 expressed by CEM and Jurkat 
cells lacks L16 expression and can therefore not reach its acti- 
vated state, thus explaining their LFA-l-independent, VLA-4- 
mediated adhesion to TNF-a-stimulated EC.  The dull ex- 
pression of the L16 epitope on resting lymphocytes corre- 
lates with the observation that the interaction of resting PBL 
is only partially mediated by LFA-1 since only a small number 
of the expressed LFA-1 molecules can become activated. 
To determine the functional activity of the LFA-1 adhe- 
sion receptors expressed on these T cells, we examined the 
capacity of these T cells to bind L cell transfectants expressing 
ICAM-1 (Fig. 2). It is known that LFA-l-mediated adhesion 
can be induced by the addition of PMA to T cells, resulting 
in high-avidity  ligand  binding (22). The LFA-1-  T  cells 
(LAD 6.6), which were used as a control, could not bind 
to blCAM-1 (Fig. 2). As expected, binding of L16 + JS136 
T cells and lymphocytes to blCAM-1 calls was induced upon 
addition of PMA, and could be blocked completely to back- 
ground levels by anti-CD18  or anti-CD54 antibodies  (not 
shown). In contrast, addition of PMA to the LFA-1  + L16- 
T cells (CEM and Jurkat) did not result in activation of  LFA-1, 
because no binding to L-ICAM-1 calls was observed. To ex- 
clude the possibility that this was caused by the relatively 
low expression  of  LFA-1 on these ceils (compared with JSD6), 
we determined the binding capacity of PBL that were briefly 
cultured in lg-2 to express approximately similar levels  of  LFA-1 
as Jurkat and CEM. In contrast to the latter two cell lines, 
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Figure 2.  Clustering ofT ceils with L-ICAM-1 ceils. Cells were differen- 
tially labeled with fluorescent dyes. Clustering was induced with (~A) or 
without (m) the addition of PMA (50 ng/ml) for 45 rain at 37~  Values 
represent  means  of duplicate  wells.  Clustering of T  cells with mock- 
transfected control cells was always <10%. One experiment  out of three 
is shown. 
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Figure 3.  Adhesion of T cells to VCAM-1. T cells were stimulated with 
(~A) or without (B) anti-ill antibody TS2/16 (10/xg/ml) for 10 min at 
4~  Subsequently, adhesion to purified VCAM-1 was performed  for 30 
min at 37~  TS2/16-induced  adhesion was blocked with an inhibitory 
anti-VLA-4 (HP2/1, 10 ~ag/rnl) antibody (l~). Adhesion to BSA was always 
<5%.  One experiment  out of two is shown. 
these L16 + lymphocytes could readily be induced by PMA 
to bind blCAM-1, demonstrating that the level of LFA-1 
expression is not limiting.  Also, other stimuli known to ac- 
tivate LFA-1 (anti-CD2, -CD3, or the addition of Mn  2+; 9, 
11, 23) were incapable of inducing the activated state of the 
LFA-1 receptor on Jurkat and CEM T  cells (not shown). 
The results from this study demonstrate that the sdective 
use of adhesion receptors in adhesion and migration oft ceUs 
into rites of  inflammation is not only regulated by an increased 
expression of the adhesion receptors' ligands ICAM-1  and 
VCAM-1 by inflammatory cytokines, such as TNF-c~, but 
is also dependent on the activated state of the adhesion  receptor 
itself,  expressed  on  the T  ceU. Expression  of the Ca  2+- 
dependent L16 epitope on LFA-1 determines ff the LFA-1 
adhesion receptor is in a "potentially active" state. Because 
L16 is a Ca2+-dependent epitope, Ca  2+ cations may play an 
important role in the formation of this conformation of  LFA-  1 
(9).  If LFA-1 expressed on T  ceils lacks the L16 epitope, 
it cannot be triggered to create a high affinity ligand binding 
form. To circtanvent this defect these cells may use the VLA-4 
receptor VCAM-1 interaction as an alternative adhesion route, 
which is used by the LFA-1- T ceUs, as wall as the Jurkat 
and CEM T cells. On the other hand, if LFA-1 on T cells 
expresses the L16 epitope,  LFA-1 mediates adhesion to en- 
dothdium, without any contribution of VLA-4 (Fig. 1). It 
is tempting to speculate that when the LFA-1/ICAM-1 in- 
teraction takes place, the VLA-4/VCAM-1 contribution in 
T cell/TNF-ot-EC interaction is downregulated through an 
unknown mechanism. Work is in progress to test this hy- 
pothesis. 
To exclude the possibility that VLA-4 expressed on JS136 
is defective, and therefore not able to mediate adhesion to 
its ligands, we determined the capacity of VLA-4, expressed 
by these different T cells, to bind VCAM-1, a ligand of  VLA-4 
(24) (Fig. 3). VLA-4 can be activated to bind VCAM-1 by 
the addition of PMA or by specific anti-/31 antibodies that 
induce the high affinity state of  VLA-4, resulting in enhanced 
binding of VLA-4 to VCAM-1 and/or FN (10, 12, 13). De- 
spite the fact that VLA-4 was not equally expressed on all 
T  cells (Table 1),  all  T  cells used  in  this  study  (LFA- 
1+/L16 +  , LFA-1+/L16 -, and LFA-1-) could be induced by 
an anti-ill antibody (TS2/16; 10) or by PMA (data not shown) 
to bind to VCAM-1 or FN (data not shown). This induced 
interaction was completely VLA-4 mediated, since anti-VLA- 
4cr  antibodies blocked the interaction.  These data indicate 
that in contrast to LFA-1, the VLA-4 receptor on all T cells 
used  in  this  study can become active to  bind VCAM-1. 
Moreover, binding ofJS136 T cells to TNF-c~-stimulated EC 
also can be enhanced by anti-B1 antibodies (10). Although 
the increase  in the total number of cells bound is limited (from 
50 to 60%), this is associated with a dear shift from LFA-1- 
mediated adhesion to a VLA-4/VCAM-l-mediated adhesion 
to EC (Fig. 4). However, if both LFA-1 and VLA-4 are acti- 
vated through the addition of PMA, JS136 T cells primarily 
use LFA-1 and not VLA-4 to bind EC, indicating that the 
LFA-1 molecule,  when activated,  dominates VLA-4 in T 
cell-EC interaction (Fig. 4). The addition of PMA to CEM 
anti- VLA-4  anti- LFA-  1 
control 
TS2/16 
PMA 
so  60  40  20  0  20  40  60  80 
Inhibition of T cell binding (%) 
Figure 4.  Contribution of LFA-1 and VLA-4 to TS2/16-induced JS136 
T cells binding to TNF-~-EC. slCr-labded T cells were aUowed to ad- 
here for 30 rain at 37~  to 24-h TNP-~x-stimuhted  EC. Adhesion was 
induced by the addition of anti-ill antibody TS2/16 (10/~g/ml) or PMA 
(50 ng/ml). Basal adhesion oft cells was 50% adhesion, and was induced 
by TS2/16 and PMA up to 60%. Values are percentages of inhibition by 
the addition  of anti-CD18  (U) or anti-VLA-4 ([]) (10/~g/ml). One ex- 
periment out of three is shown. 
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sion to EC into a LFA-l-dependent adhesion, providing fur- 
ther evidence that their LFA-1 molecules are not functional 
(not  shown). 
It should be noted that binding of T ceils to isolated ligands 
(ICAM-1, VCAM-1, and FN) or ligands expressed by trans- 
fected L cells is low unless the T cells are activated by PMA 
or other stimuli, inducing a high affinity state of the integrin 
receptor (9, 13, 25). Nevertheless, we consistently observed 
strong binding of the calls used in this study to EC via these 
ligands  (ICAM-1  and VCAM-1).  This suggests that  other 
interactions precede engagement of LFA-1 or VLA-4, as has 
been demonstrated for ELAM-1 (26). It can be excluded that 
E-selectin and L-selectin are involved in this process (26, 27). 
Activated T cells lack L-selectin expression, whereas E-sdectin 
expression is low on EC after prolonged (24-h) exposure to 
TNF-oe (Table 1). This indicates that other, undefined mole- 
cules expressed by these T  ceils may induce high  affinity 
binding  of VLA-4  or  LFA-1,  upon  binding  of TNF-oe- 
stimulated EC. One possible candidate is CD31, which has 
recently been described to stimulate 131- and 132-mediated adhe- 
sion of T cell subsets to VCAM-1 and ICAM-1 (28). CD31 
seems  to  preferentially  stimulate  131-mediated  adhesion, 
whereas in our study, 132-mediated adhesion seems to domi- 
nate/31-mediated adhesion, suggesting that also other mole- 
cules may be involved. 
Since transendothelial migration of T cells mainly involves 
the LFA-1/ICAM-1 interaction  (29),  and not the VLA-4/ 
VCAM-1 interaction, the absence of the L16 epitope on LFA-1 
can have serious effects on the transendothelial migration ca- 
pacity of LFA-l+L16-  T  cells.  Indeed, it has been reported 
that migration of LFA-1-  (LAD) T  ceils through EC is se- 
verely affected by the absence of LFA-1 (30).  We therefore 
assume that  LFA-1 +  T  cells,  which lack the L16 epitope, 
show binding to EC using VLA-4, but migrate poorly through 
EC. In contrast, LFA-l+L16 + T  cells will readily bind EC, 
and migrate through EC using high affinity LFA-1. This may 
provide the immune system with a mechanism by which pref- 
erentially activated LFA-l+L16 + T  calls will be capable of 
migrating into tissues and actively participating in the effector 
phase of an inflammatory/immune  response. 
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